Company Filing History:
Years Active: 2025
Title: Shunsuke Takashima: Innovator in Medicinal Chemistry
Introduction
Shunsuke Takashima is a notable inventor based in Kyoto, Japan. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that address diseases associated with oxidative stress. His innovative work has led to the creation of a patent that holds promise for various medical applications.
Latest Patents
Shunsuke Takashima holds a patent for a benzotriazole compound. This invention aims to provide a medicament capable of treating and/or preventing diseases associated with oxidative stress by inhibiting the protein-protein interaction between Keap1 and Nrf2, thereby activating Nrf2. The patent describes a compound represented by a specific formula, or a pharmaceutically acceptable salt thereof. The medicament is intended for the prophylaxis and/or treatment of diseases such as chronic kidney disease, non-alcoholic steatohepatitis, chronic obstructive pulmonary disease, and several others, including Parkinson's disease and glaucoma. He has 1 patent to his name.
Career Highlights
Throughout his career, Shunsuke Takashima has worked with prominent companies in the pharmaceutical industry. Notably, he has been associated with Daiichi Sankyo Company, Limited and Kyoto Pharmaceutical Industries, Ltd. His work in these organizations has contributed to advancements in drug development and therapeutic solutions.
Collaborations
Shunsuke Takashima has collaborated with esteemed colleagues in his field, including Yoshihiro Ogura and Rieko Takano. These partnerships have fostered innovation and have been instrumental in the progress of his research endeavors.
Conclusion
Shunsuke Takashima is a distinguished inventor whose work in medicinal chemistry has the potential to impact the treatment of various diseases. His innovative contributions, particularly in the development of benzotriazole compounds, highlight the importance of research in addressing health challenges.